- Home
- CPT vs RPRX Comparison
CPT vs RPRX Comparison
Compare CPT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPT
- RPRX
- Stock Information
- Founded
- CPT 1993
- RPRX 1996
- Country
- CPT United States
- RPRX United States
- Employees
- CPT N/A
- RPRX N/A
- Industry
- CPT Real Estate Investment Trusts
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CPT Real Estate
- RPRX Health Care
- Exchange
- CPT Nasdaq
- RPRX Nasdaq
- Market Cap
- CPT 12.2B
- RPRX 14.0B
- IPO Year
- CPT 1993
- RPRX 2020
- Fundamental
- Price
- CPT $119.84
- RPRX $33.42
- Analyst Decision
- CPT Buy
- RPRX Strong Buy
- Analyst Count
- CPT 20
- RPRX 6
- Target Price
- CPT $125.48
- RPRX $41.67
- AVG Volume (30 Days)
- CPT 917.9K
- RPRX 4.7M
- Earning Date
- CPT 02-06-2025
- RPRX 02-11-2025
- Dividend Yield
- CPT 3.50%
- RPRX 2.63%
- EPS Growth
- CPT N/A
- RPRX N/A
- EPS
- CPT 1.50
- RPRX 1.91
- Revenue
- CPT $1,555,399,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- CPT N/A
- RPRX $29.18
- Revenue Next Year
- CPT $3.96
- RPRX $9.99
- P/E Ratio
- CPT $79.93
- RPRX $17.48
- Revenue Growth
- CPT 0.58
- RPRX N/A
- 52 Week Low
- CPT $92.26
- RPRX $24.05
- 52 Week High
- CPT $127.69
- RPRX $33.69
- Technical
- Relative Strength Index (RSI)
- CPT 60.42
- RPRX 78.16
- Support Level
- CPT $117.56
- RPRX $32.28
- Resistance Level
- CPT $121.50
- RPRX $33.69
- Average True Range (ATR)
- CPT 2.43
- RPRX 0.69
- MACD
- CPT 0.44
- RPRX -0.02
- Stochastic Oscillator
- CPT 83.53
- RPRX 89.85
About CPT Camden Property Trust
Camden Property Trust is a real estate investment trust primarily engaged in the acquisition, management, and development of multifamily apartment communities across the United States. The company's real estate portfolio consists primarily of apartment properties throughout the Sun Belt. Houston, Dallas, Las Vegas, and Atlanta represent some of Camden's largest housing markets in terms of apartment units. The firm derives nearly all of its revenue from the leasing of properties to tenants through short-term agreements. Camden Property derives the majority of its revenue from the Washington D.C., Los Angeles, Houston, Atlanta, and southeastern Florida areas.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.